The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Paraoxonase (PON1) Phenotype Is a Better Predictor of Vascular Disease Than Is PON1 192 or PON1 55 Genotype
Open accessAbstract
Abstract —The paraoxonase (PON1) PON1-Q192R and PON1-L55M polymorphisms have been inconsistently associated with vascular disease. Plasma PON1 activity phenotypes vary markedly within genotypes and were, therefore, expected to add to the informativeness of genotype for predicting vascular disease. The case-control sample included 212 age- and race-matched men (mean age 66.4 years). The 106 carotid artery disease (CAAD) cases had >80% carotid stenosis, and the 106 controls had <15%. Two PON1 substrate hydrolysis rates (paraoxon [POase] and diazoxon [DZOase]) were significantly lower in cases than in controls and were significant predictors of CAAD by use of logistic regression (POase, P =0.005; DZOase, P =0.019). DZOase predicted vascular disease independently of lipoprotein profile, high density lipoprotein subfractions, apolipoprotein A-I, and smoking. PON1-192 and PON1-55 genotypes or haplotypes did not predict case-control status unless the activity phenotype was also included as a predictor by use of logistic regression. When phenotype was included as a predictor, PON1-192 and PON1-55 genotypes or combined haplotypes were significant predictors ( P <0.05). In conclusion, examining PON1-192 and/or PON1-55 genotypes alone may mistakenly lead to the conclusion that there is no role of PON1 in CAAD. These results support the benefit of a “level crossing” approach that includes intervening phenotypes in the study of complexly inherited disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
A simple salting out procedure for extracting DNA from human nucleated cells
Miller, S. A., Dykes, D. D., & Polesky, H. F. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.3.1215 · Cited by 20,330
Warnick, G. R., Benderson, J., & Albers, J. J. (1982) · Clinical Chemistry · doi:10.1093/clinchem/28.6.1379 · Cited by 2,159
Watson, A. D., Berliner, J. A., Hama, S. Y., La Du, B. N., Faull, K. F., Fogelman, A. M., & Navab, M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118359 · Cited by 1,154
Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
Shih, D. M., Gu, L., Xia, Y.-R., Navab, M., Li, W.-F., Hama, S., Castellani, L. W., Furlong, C. E., Costa, L. G., Fogelman, A. M., et al. (1998) · Nature · doi:10.1038/28406 · Cited by 1,078
Self-citationThe molecular basis of the human serum paraoxonase activity polymorphism
Humbert, R., Adler, D. A., Disteche, C. M., Hassett, C., Omiecinski, C. J., & Furlong, C. E. (1993) · Nature Genetics · doi:10.1038/ng0193-73 · Cited by 841
Self-citationMACKNESS, M., ARROL, S., ABBOTT, C., & DURRINGTON, P. (1993) · Atherosclerosis · doi:10.1016/0021-9150(93)90183-u · Cited by 816
The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin
Davies, H. G., Richter, R. J., Keifer, M., Broomfield, C. A., Sowalla, J., & Furlong, C. E. (1996) · Nature Genetics · doi:10.1038/ng1196-334 · Cited by 603
Self-citationAviram, M., Rosenblat, M., Billecke, S., Erogul, J., Sorenson, R., Bisgaier, C. L., Newton, R. S., & La Du, B. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(98)00272-x · Cited by 596
Garin, M. C., James, R. W., Dussoix, P., Blanché, H., Passa, P., Froguel, P., & Ruiz, J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119134 · Cited by 476
Enzymatic methods for quantification of lipoprotein lipids
Warnick, G. R. (1986) · Methods in Enzymology · doi:10.1016/0076-6879(86)29064-3 · Cited by 393
Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes
Ruiz, J., Morabia, A., Blanche, H., James, R. W., Garin, M.-C. B., Charpentier, G., Passa, P., Vaisse, C., Ruiz, J., & Froguel, P. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92709-3 · Cited by 344
Marcovina, S. M., Albers, J. J., Henderson, L. O., & Hannon, W. H. (1993) · Clinical Chemistry · doi:10.1093/clinchem/39.5.773 · Cited by 342
Serrato, M., & Marian, A. J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118373 · Cited by 339
Serum Paraoxonase After Myocardial Infarction
Ayub, A., Mackness, M. I., Arrol, S., Mackness, B., Patel, J., & Durrington, P. N. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.2.330 · Cited by 287
Determination of paraoxonase (PON1) status requires more than genotyping
Richter, R. J., & Furlong, C. E. (1999) · Pharmacogenetics · doi:10.1097/00008571-199912000-00009 · Cited by 281
Self-citationPrecipitation methods for quantification of lipoproteins
Bachorik, P. S., & Albers, J. J. (1986) · Methods in Enzymology · doi:10.1016/0076-6879(86)29063-1 · Cited by 279
Mackness, B., Mackness, M. I., Arrol, S., Turkie, W., & Durrington, P. N. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701390 · Cited by 211
Nishio, E., & Watanabe, Y. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6961 · Cited by 171
Ikeda, Y., Suehiro, T., Inoue, M., Nakauchi, Y., Morita, T., Arii, K., Ito, H., Kumon, Y., & Hashimoto, K. (1998) · Metabolism · doi:10.1016/s0026-0495(98)90246-3 · Cited by 153
Genetic polymorphism and interethnic variability of plasma paroxonase activity.
Playfer, J. R., Eze, L. C., Bullen, M. F., & Evans, D. A. P. (1976) · Journal of Medical Genetics · doi:10.1136/jmg.13.5.337 · Cited by 146
Garin, M. C., Abbott, C. A., Messmer, S., Mackness, M., Durrington, P. N., Pometta, D., & James, R. W. (1994) · Biochemical Journal · doi:10.1042/bj3040549 · Cited by 129
Pfohl, M., Koch, M., Enderle, M., Kühn, R., Füllhase, J., Karsch, K. R., & Häring, H.-U. (1999) · Diabetes · doi:10.2337/diabetes.48.3.623 · Cited by 125
Graham, A., Hassall, D. G., Rafique, S., & Owen, J. S. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(97)00162-7 · Cited by 88
Multiple Genetic Determinants of Variation of Plasma Lipoproteins in Alberta Hutterites
Hegele, R. A., Brunt, J., & Connelly, P. W. (1995) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.15.7.861 · Cited by 81
Boright, A. P., Connelly, P. W., Brunt, J., Scherer, S. W., Tsui, L., & Hegele, R. A. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)00071-9 · Cited by 68
Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype
Brophy, V. H., Jarvik, G. P., Richter, R. J., Rozek, L. S., Schellenberg, G. D., & Furlong, C. E. (2000) · Pharmacogenetics · doi:10.1097/00008571-200007000-00008 · Cited by 56
Self-citation
Cited by
Mapping complex disease loci in whole-genome association studies
Carlson, C. S., Eberle, M. A., Kruglyak, L., & Nickerson, D. A. (2004) · Nature · doi:10.1038/nature02623 · Cited by 620
Modulation of paraoxonase (PON1) activity
Costa, L. G., Vitalone, A., Cole, T. B., & Furlong, C. E. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.08.027 · Cited by 488
Self-citationDecreased Atherosclerotic Lesion Formation in Human Serum Paraoxonase Transgenic Mice
Tward, A., Xia, Y.-R., Wang, X.-P., Shi, Y.-S., Park, C., Castellani, L. W., Lusis, A. J., & Shih, D. M. (2002) · Circulation · doi:10.1161/01.cir.0000023623.87083.4f · Cited by 455
Mackness, B., Davies, G. K., Turkie, W., Lee, E., Roberts, D. H., Hill, E., Roberts, C., Durrington, P. N., & Mackness, M. I. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq0901.094247 · Cited by 435
The Molecular-Genetic Basis of Functional Hyperandrogenism and the Polycystic Ovary Syndrome
Escobar-Morreale, H. F., Luque-Ramírez, M., & San Millán, J. L. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0004 · Cited by 422
Metadata
- Authors
- Jarvik, G. P., Rozek, L. S., Brophy, V. H., Hatsukami, T. S., Richter, R. J., Schellenberg, G. D., & Furlong, C. E.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2000-11
- Volume
- 20
- Issue
- 11
- Pages
- 2441-2447
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2008378566
- Cited by
- 309
- References
- 27
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.